论文部分内容阅读
本文利用免疫组化(LSAB)法,Feulgen染色及图像分析技术对乳腺癌84例和乳腺良性病变22例进行检测。结果:(1)CerbB2蛋白免疫组化染色的着色面积与着色深度高度相关(P<001)。(2)CerbB2阳性表达全部为恶性肿瘤,总表达率为33%。在不同年龄、肿瘤分级以及淋巴转移情况之间CerbB2阳性表达率差别无统计学意义。(3)CerbB2免疫组化染色的平均光密度与DNA倍体水平高度正相关(P<001)。(4)CerbB2阳性肿瘤的细胞形态参数均显著大于阴性肿瘤。结论∶乳腺良恶性病变中,CerbB2癌基因激活仅见于乳腺癌,对乳腺癌的诊断有意义,对预后判断只起辅助作用
In this paper, 84 cases of breast cancer and 22 cases of benign breast lesions were detected by immunohistochemistry (LSAB), Feulgen staining and image analysis techniques. Results: (1) The staining area of CerbB2 protein immunohistochemical staining was highly correlated with the depth of staining (P<001). (2) The positive expression of CerbB2 was all malignant and the total expression rate was 33%. There was no significant difference in the positive expression rate of C-erbB-2 between different ages, tumor grade, and lymphatic metastasis. (3) The average optical density of CerbB2 immunohistochemical staining was positively correlated with DNA ploidy level (P<001). (4) The cell morphological parameters of CerbB2 positive tumors were significantly greater than those of negative tumors. Conclusion: In breast benign and malignant lesions, CerbB2 oncogene activation is only found in breast cancer. It is meaningful for the diagnosis of breast cancer and only plays a role in determining prognosis.